Peer Review History
| Original SubmissionNovember 10, 2025 |
|---|
|
User-centered design and co-creation for digital health Innovations and diagnostics: A scoping review protocol to explore applications and outcomes in low-resource settings PLOS One Dear Dr. Otukpa, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 27 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Helen Howard Staff Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Thank you for stating the following financial disclosure: “This research is funded by the European Health and Digital Executive Agency (HADEA) Project 101057251 – DI-DIDA” Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 3. Please provide a complete Data Availability Statement in the submission form, ensuring you include all necessary access information or a reason for why you are unable to make your data freely accessible. If your research concerns only data provided within your submission, please write "All data are in the manuscript and/or supporting information files" as your Data Availability Statement. 4. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process. 5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 6. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Additional Editor Comments: Please note that we have only been able to secure a single reviewer to assess your manuscript. We are issuing a decision on your manuscript at this point to prevent further delays in the evaluation of your manuscript. Please be aware that the editor who handles your revised manuscript might find it necessary to invite additional reviewers to assess this work once the revised manuscript is submitted. However, we will aim to proceed on the basis of this single review if possible. Could you please revise the manuscript to carefully address the concerns raised? [Note: HTML markup is below. Please do not edit.] Reviewer's Responses to Questions Comments to the Author 1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions? Reviewer #1: Partly ********** 2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses??> Reviewer #1: Partly ********** 3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable??> Reviewer #1: No ********** 4. Have the authors described where all data underlying the findings will be made available when the study is complete??> The PLOS Data policy Reviewer #1: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes ********** Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics. You may also provide optional suggestions and comments to authors that they might find helpful in planning their study. Reviewer #1: This protocol proposes a scoping review on the use of user-centred design (UCD) and co-creation methods for digital health interventions in low-resource settings. While this topic is interesting overall, the manuscript has significant issues that should be addressed before publication. Please see below for more specific feedback. Major: 1. The framing and motivation for the scoping review is not clear. In particular, in the introduction, it is not consistently clear that you are focusing on identifying papers that use UCD to design digital health interventions in low-resource settings. You mention digital health early on but then switch to talking about UCD and low-resource settings without digital health. 2. The introduction/framing of the paper only mentions UCD and co-creation but there are many other related methodologies such as co-design, participatory design, human-centred design (HCD), etc. You use the term HCD in line 105 but did not introduce it. The paper would benefit from clearly defining the term(s) you plan to use, and explaining how they relate to other similar methodologies, and explaining in your search strategy how you will capture as many of these as possible. 3. Intro, line 115-119: You have not made a strong case for why UCD and co-creation methodologies would need to be applied differently in a low-resource setting. The factors you list here could impact the success of digital health interventions, but not UCD methods. In fact, I would argue that UCD methods help to overcome these types of challenges in digital health in low-resource settings. 4. Line 148: Your third research question cannot be addressed with your planned methods. You would need to also identify studies that do not use UCD methods in order to compare them. 5. Methods: Your methods are not very clearly explained and are ambiguous in places. For example, the dates that will be included are not clear (some places say 10 year, some say 10-15). It would help to include an overview of the search strategy in the main paper, rather than the appendix (e.g., summarising the main search concepts and synonyms). It would also be helpful to have the databases that will be searched clearly listed (they are currently mentioned across different paragraphs, and a more detailed strategy is needed for Google Scholar which usually returns tens of thousands of results that cannot be systematically screened), as well as the inclusion/exclusion criteria. I would also suggest presenting your methods in the order they will be done. For example, you write that references of included articles will be screened before you have finished describing where the searches will take place. I see that you have checked these items off in the PRISMA checklist, but they did not feel very clear in the protocol. 6. It would be helpful to more clearly define if there are certain types of papers that will be included or excluded. Do they have to measure outcomes to be included? What if they only use co-design methods to develop a digital health tool, but do not evaluate it? Do they need to measure the outcomes you have specifically listed? What if they only mention the use of “UCD” or “co-design” but do not explicitly describe the methods used? Minor comments: 7. Intro: in some areas, this protocol focuses on infectious disease specifically, though this does not seem to be part of the scoping review topic or strategy. I would suggest instead starting the introduction by talking about the burden of preventable diseases in low-resource settings, rather than listing rare infectious diseases of poverty. 8. Intro: Similarly, many of the digital health examples provided are very infectious-disease specific. If you plan to review studies that include all types of digital health tools, I think these examples should be expanded to include those that address health behaviours, chronic diseases, etc. as these are a huge area as well. 9. Line 146: I think this question needs to include “in low-resource settings.” 10. Please clarify how you will you define “low-resource” or “underserved” in high-income countries as part of your inclusion/exclusion criteria. 11. Types of studies: it is not typical to include systematic/scoping reviews in your results, but instead to check their references for relevant studies. 12. Line 175: you mentioned a restriction of 10 years in your abstract but state in Line 175 that you will just “prioritise” publications in 10-15 years but not restrict them. Since this is a systematic search and screening, there is no scope to prioritise – you either need to include the papers or not. Please also choose between 10 or 15 years. If you decide to restrict the strategy, please provide a justification. 13. Search strategy: The search strategy needs refinement – for example, you are missing the other spelling of “human-centred design” and many digital health-relevant terms like electronic medical records, electronic health records, chatbot, etc. 14. Ethics: scoping reviews do not require ethics approval. 15. Extraction table (appendix): it would also be helpful to extract data on the any specific framework that was used by the researchers (e.g., the Double Diamond, IDEAS framework, etc.). This also seems closely related to your first review question. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. |
| Revision 1 |
|
Dear Dr. Otukpa, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Sep 18 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Alejandro F. Mac Cawley, Ph.D. Academic Editor PLOS One Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments: The reviewers have raised some remaining issues that should be addressed. Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions? Reviewer #1: Partly Reviewer #2: Yes Reviewer #3: Yes ********** 2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses??> Reviewer #1: Partly Reviewer #2: Yes Reviewer #3: Yes ********** 3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable??> Reviewer #1: No Reviewer #2: Yes Reviewer #3: Yes ********** 4. Have the authors described where all data underlying the findings will be made available when the study is complete??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics. You may also provide optional suggestions and comments to authors that they might find helpful in planning their study. Reviewer #1: The authors have responded to many of my earlier comments and the manuscript is improved. However, there are still some remaining issues that should be addressed in order for this protocol to be clearly reported, rigorous, and replicable. Please see below for my additional feedback: 1. Line 59: Given the global focus of the review, the frequent mentions of SSA in the Intro don’t make sense. I would suggest moving away from SSA and describing challenges across LMICs more broadly. 2. Intro: The introduction still does not define HCD or discuss it in relation to other defined concepts like UCD or co-creation (Line 172). The justification for the focus on UCD and co-creation is also not very strong – why have UCD and co-creation been chosen as the focus, but not HCD or any other participatory methods? The framing needs to be very clear – if all of these methods are included in the review, then more elaboration is needed on the group of methods as a whole, rather than only highlighting two approaches. You could consider replacing “UCD and co-creation” throughout the paper with “UCD and related methodologies” or similar. 3. Line 166: there is a typo where what should be one sentence has been broken into multiple sentences. 4. Line 191: questions 1 and 2 do not mention UCD, though this was one of the main methodologies identified in the Intro. Again, it would be helpful to define a specific focus (I would advocate for including all participatory approaches together for a scoping review of this nature), then to be sure it is consistently applied across the research questions, search methods, etc. 5. Line 203: couldn’t “diagnostic innovations” already fit under the umbrella of digital health? It feels like you are mentioning a sub-area of digital health somewhat randomly, and only in some places of the protocol. This also applies to the title. 6. Line 210: From “Particularly…” onwards - you do not need to talk about these aspects of the inclusion criteria in the “population/setting” section. They fit better in later sections. 7. Line 233: I would argue that including papers that explicitly state they have used these methods but without describing the relevant activities should be included, given your point in the introduction about this being a problem in the field. This seems that it would then be a finding of your review if some proportion of the papers mention UCD/HCD/co-design, etc. but do not explicitly describe their methods. 8. Line 242: Search should not stop at 2025, but should go until the present 9. Line 251: reference needed for JBI 10. Line 260: do you mean “peer-reviewed literature” or “academic literature” and “grey literature” instead of “published” and “unpublished”? 11. Line 276: I don’t think #6 should be included in your search – this could exclude relevant papers that refer to high-resource settings, or papers in high-income countries that focus on low-resource communities or populations. Similarly, if you want to include papers focused on underserved communities in high-income settings, as stated in your Methods, you should include search terms related to these populations (e.g., underserved, low-income, marginalised, etc.) 12. Line 305: the editor can make the final call here, but I don’t think you need to mention these ethics approvals – they are not relevant for this scoping review and just take up unnecessary space, in my opinion. 13. Line 318: it appears that this search has already been conducted, but this is concerning as I have identified issues with the search terms that I think need to be corrected before the scoping review is completed. 14. Line 493: You should state in the protocol where the list of LMICs came from (e.g. World Bank classification and year) – this is currently only in your response to my comment, but not in the Methods. 15. Line 271: “In several electronic databases” is vague - it is still not very clear which databases will be searched. It is also not yet clear how grey literature will be located, as “grey literature sources” is quite vague too. 16. Appendix: you are missing search terms with the British spelling of “human-centred” and “user-centred” Reviewer #2: - The introduction is well structured and clearly motivates the review. However, some technology-specific examples (e.g., malaria diagnostics, wearable monitoring, and point-of-care technologies) are described in greater detail than is necessary for a protocol. As the review focuses on UCD and co-creation rather than digital health technologies themselves, these examples could be condensed to place greater emphasis on the conceptual rationale and the implementation challenges motivating the review. - The operational definition of “low-resource settings” requires further clarification. The eligibility criteria currently include LMICs as well as rural or underserved areas in high-income countries, but it is not clear why the latter are included or how they will be identified during screening. Rurality or underserved status does not necessarily equate to a low-resource setting. The authors should either (i) adopt a standard definition (e.g., World Bank LMIC classification), or (ii) provide a clear conceptual and operational justification for extending the review to resource-constrained populations within high-income countries, including explicit eligibility criteria. - The “Study status and timeline” section appears to contain projected dates that have now passed. Please update this section to reflect the current status of the review (e.g., whether the literature search, screening, or data extraction have been completed). If the review has progressed since the protocol was first submitted, it would be helpful to clarify that the protocol continues to reflect the methods that were followed, and that any deviations will be reported in the final review. - RQ2 asks: “How do co-creation processes influence…”. But, a scoping review maps reported evidence rather than demonstrating causal influence. A more cautious wording could be: “How are co-creation processes reported to influence…”. - limitations may also acknoledge language restriction (English/French), and the anticipated heterogeneity of interventions, co-creation approaches, and reported outcomes, which may limit the comparability of findings. Reviewer #3: I have carefully examined both the authors' response to the previous reviewer and the revised manuscript. The authors have made substantial efforts to address the concerns raised, and the manuscript has improved considerably. In particular, the scope of the review is now more clearly defined, the rationale is better aligned with the stated objectives, the review questions are more appropriate for a scoping review methodology, and the methodological description is more transparent and reproducible. The revised protocol is generally well organised and follows accepted guidance for scoping reviews. Overall, these revisions adequately address the substantive concerns raised by the previous reviewer. I only have a small number of minor observations before acceptance. 1. The Introduction remains somewhat lengthy- Although the broader examples of digital health have improved the manuscript, several sections describing individual technologies (for example wearable technologies, disease-specific examples and technical descriptions) appear more detailed than is necessary for a protocol. Some condensation would improve readability without affecting the scientific contribution. This is an editorial suggestion rather than a methodological concern. 2. The rationale could be slightly more concise- While the rationale is now much stronger, there remains some repetition around the value of documenting UCD/co-creation and the need for evidence mapping. Streamlining this section would improve flow. 3. A final proofread would be beneficial- I noticed occasional grammatical and stylistic inconsistencies (for example punctuation, sentence flow and wording) that would benefit from careful copy-editing prior to publication. These do not affect the scientific content but would improve readability. The authors have responded appropriately and comprehensively to the previous review. The remaining observations are minor editorial suggestions rather than substantive methodological concerns. I therefore recommend acceptance after minor editorial revisions. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: No Reviewer #3: Yes: Maneesh Kumar ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. |
| Revision 2 |
|
User-centered design and related participatory approaches in digital health innovations for low-resource settings: A scoping review protocol PONE-D-25-59947R2 Dear Dr. Otukpa, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Alejandro F. Mac Cawley, Ph.D. Academic Editor PLOS One Additional Editor Comments (optional): I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions? Reviewer #2: Yes ********** 2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses??> Reviewer #2: Yes ********** 3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable??> Reviewer #2: Yes ********** 4. Have the authors described where all data underlying the findings will be made available when the study is complete??> The PLOS Data policy Reviewer #2: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #2: Yes ********** Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics. You may also provide optional suggestions and comments to authors that they might find helpful in planning their study. Reviewer #2: I appreciate the authors' careful and comprehensive responses. The manuscript has improved substantially, particularly in the conceptual framing, operational definition of low-resource settings, clarification of the study status, refinement of the review questions, and transparency of the protocol limitations. I believe the major methodological concerns raised in the previous review have been satisfactorily addressed. Before publication I recommend one final consistency review to ensure that terminology is used uniformly throughout, particularly for:UCD and related participatory design approaches, digital health innovations, low-resource settings etc. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #2: No ********** |
| Formally Accepted |
|
PONE-D-25-59947R2 PLOS One Dear Dr. Otukpa, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS One and supporting open access. Kind regards, PLOS One Editorial Office Staff on behalf of Dr. Alejandro F. Mac Cawley Academic Editor PLOS One |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .